TITLE

First new lupus drug approved in half century

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
April 2011
SOURCE
American Journal of Health-System Pharmacy;4/15/2011, Vol. 68 Issue 8, p646
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports the Food and Drug Administration (FDA) approval for belimumab for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). The drug is to be marketed as Benlysta by Human Genome Sciences and GlaxoSmithKline. The drug's labelling details, including its undesirable effects, contra-indications and instructions for dose preparation and its pharmacological properties are also presented. INSET: New drugs and dosage forms.
ACCESSION #
59982635

 

Related Articles

  • Belimumab. Sanz, Iñaki; Yasothan, Uma; Kirkpatrick, Peter; Sanz, Iñaki // Nature Reviews Drug Discovery;May2011, Vol. 10 Issue 5, p335 

    In March 2011, belimumab (Benlysta; Human Genome Sciences/GlaxoSmithKline), a human monoclonal antibody that is specific for the cytokine B lymphocyte stimulator, was approved by the US Food and Drug Administration (FDA) for the treatment of systemic lupus erythematosus.

  • FDA actions.  // Clinical Cardiology Alert;May2011 Pharmacology, p2 

    The article offers updates on several Food and Drug Administration (FDA) actions. Belimumab, marketed as 'Benlysta' by GlaxoSmithKline, is approved for systemic lupus erythematosus (SLE). Roflumilast, a phosphodiesterase type 4 inhibitor, marketed as 'Daliresp' by Forest Pharmaceuticals, is...

  • FDA actions. Elliott, William T. // Primary Care Reports;May2011 Pharmacology Watch, p2 

    This section offers news briefs from the U.S. Food & Drug Administration (FDA). Belimumab has been approved for the treatment of patients with lupus and is marketed as Benlysta by GlaxoSmithKline. Roflumilast, marketed as Daliresp by Forest Pharmaceuticals, has been cleared for patients with...

  • FDA actions.  // Clinical Oncology Alert;May2011 Supplement 2, p2 

    The article offers updates on several Food and Drug Administration (FDA) actions. Belimumab, marketed as 'Benlysta' by GlaxoSmithKline, is approved for systemic lupus erythematosus (SLE). Roflumilast, a phosphodiesterase type 4 inhibitor, marketed as 'Daliresp' by Forest Pharmaceuticals, is...

  • FDA arthritis advisory committee votes 13-2 in favor of approving lupus biologic drug. Kassan, Stuart S.; Rapp, Susan M. // Orthopedics Today;Dec2010, Vol. 30 Issue 12, p56 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to support the biologic license application for the belimumab drug.

  • Denosumab Receives Conditional Approval from FDA Expert Panel. Elliott, William T. // Neurology Alert;Oct2009 Pharmacology Watch, p2 

    The article reports that a condition approval has been given to Denosumab, a new human monoclonal antibody, by a Food and Drug Administration (FDA) Expert Panel. The agency is testing the drug for treatment of osteoporosis in men and women. The drug would be branded as Proliaâ„¢ by Amgen...

  • Denosumab approved to prevent cancer-related bone injury in metastatic cancer. Harris, Jason // Hem/Onc Today;12/10/2010, Vol. 11 Issue 23, p5 

    The article announces the U.S. Food and Drug Administration's approval of denosumab for the preventive treatment of skeletal-related events in patients with cancer metastasized into the bone.

  • FDA approves eculizumab for atypical hemolytic uremic syndrome.  // Hem/Onc Today;10/25/2011, Vol. 12 Issue 20, p4 

    The article reports on the approval of the monoclonal antibody eculizumab from Soliris and Alexion Pharmaceuticals by the U.S. Food and Drug Administration (FDA) for the treatment of hemolytic uremic syndrome.

  • Dinutuximab: First and only agent for treating a rare pediatric cancer. JALLOH, MOHAMED // Pharmacy Today;May2015, Vol. 21 Issue 5, p41 

    The article reports that the U.S. Food and Drug Administration has granted approval for the use of Dinutuximab, monoclonal antibody that binds to a glycolipid on the surface of neuroblastoma cells, in pediatric patients with high-risk neuroblastoma. Topics discussed include views of Porscha...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics